In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Statistics Quarterly, Q2 2006

Executive Summary

In this issue, we present another installment of our quarterly review of dealmaking-for April-June 2006. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.

You may also be interested in...

Siemens acquires Bayer Diagnostics, Creates Integrated Diagnostics Powerhouse

Following upon its announcement in May that it would pay $1.86 billion for Diagnostics Products, to bring an immunodiagnostics business in-house, Siemens announced in June that it will acquire Bayer Diagnostics for approximately €4.2 billion or $5.26 billion. Siemens thus catapults itself to the number two spot in the immunodiagnostics segment of IVD, after Roche, and by its calculations, now plays a close third to Abbott Laboratories in the overall in vitro diagnostics market.

Vertex/J&J: Pushing Big Pharma's Deal Flexibility to the Limit

Vertex Pharmaceuticals deal with Johnson & Johnson for its Phase II hepatitis C protease inhibitor VX-950 underscore the significant potential for HCV protease inhibitors to alter the landscape of disease treatment and suggests pharmaceutical dealmakers will have to be ever more flexible to land biotech's best products.

FibroGen Wins Big Upfront, Keeps US Rights to Oral Anemia Drug

Astellas Pharma badly wanted to expand its rights to FibroGen's oral anemia compounds beyond Japan. So badly, in fact, that it paid a whopping $300 million up front, agreed to up to $465 million in pre-approval milestones, and will fund half of the compounds' development in Europe and North America. Yet Astellas doesn't even get North American commercial rights in exchange: it had to settle for European and other ex-US territories.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts